Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation

• Published in: Pharmacogenetics and genomics Vol. 27; no. 9; p. 329
• Main Authors: Ueshima, Satoshi, Hira, Daiki, Fujii, Ryo, Kimura, Yuuma, Tomitsuka, Chiho, Yamane, Takuya, Tabuchi, Yohei, Ozawa, Tomoya, Itoh, Hideki, Horie, Minoru, Terada, Tomohiro, Katsura, Toshiya
• Format: Journal Article
• Language: English
• Published: United States 01.09.2017
• Subjects: Adult; Aged; Aged, 80 and over; Anticoagulants - adverse effects; Anticoagulants - blood; Anticoagulants - pharmacokinetics; ATP Binding Cassette Transporter, Sub-Family B - genetics; ATP Binding Cassette Transporter, Sub-Family G, Member 2 - genetics; Atrial Fibrillation - blood; Atrial Fibrillation - drug therapy; Atrial Fibrillation - genetics; Atrial Fibrillation - pathology; Cytochrome P-450 CYP3A - genetics; Factor X - antagonists & inhibitors; Female; Genotype; Glomerular Filtration Rate - drug effects; Hemorrhage - chemically induced; Hemorrhage - genetics; Hemorrhage - pathology; Humans; Male; Middle Aged; Neoplasm Proteins - genetics; Polymorphism, Single Nucleotide; Pyrazoles - adverse effects; Pyrazoles - blood; Pyrazoles - pharmacokinetics; Pyridones - adverse effects; Pyridones - blood; Pyridones - pharmacokinetics

During anticoagulant therapy, major bleeding is one of the most severe adverse effects. This study aimed to evaluate the relationships between ABCB1, ABCG2, and CYP3A5 polymorphisms and plasma trough concentrations of apixaban, a direct inhibitor of coagulation factor X. A total of 70 plasma concent...